IDEAYA Biosciences Inc. (NASDAQ: IDYA) announced the pricing of an underwritten public offering of common stock and pre-funded warrants expected to generate approximately $300 million in gross proceeds.

The South San Francisco-based precision medicine oncology company is selling 5,555,556 shares of common stock at $27.00 per share and pre-funded warrants to purchase 5,555,576 shares at $26.9999 per warrant. The pre-funded warrants carry an exercise price of $0.0001 per share.

IDEAYA has granted underwriters a 30-day option to purchase up to an additional 1,666,669 shares at the public offering price. The offering is expected to close on or about June 10, 2026, subject to customary closing conditions.

J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are serving as joint book-running managers for the offering, while Wedbush PacGrow is acting as lead manager.

The securities are being offered pursuant to an automatically effective shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission. The offering is being conducted through a written prospectus and prospectus supplement.

IDEAYA focuses on discovering and developing targeted therapies for cancer, with a pipeline centered on synthetic lethality and antibody-drug conjugates for molecularly defined solid tumor indications.